SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN
May 23 (Reuters) - SpringWorks Therapeutics Inc SWTX.O:
SPRINGWORKS THERAPEUTICS RECEIVES POSITIVE CHMP OPINION FOR MIRDAMETINIB FOR TREATMENT OF ADULT AND PEDIATRIC PATIENTS WITH NF1-PN
SPRINGWORKS THERAPEUTICS INC: DECISION FROM EUROPEAN COMMISSION EXPECTED IN Q3 2025
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.